Core Viewpoint - Skye Bioscience, Inc. announced promising preclinical data for its CB1 antibody, nimacimab, indicating significant weight loss in a murine diet-induced obesity model, suggesting potential as a treatment for obesity and metabolic disorders [1][2][5] Group 1: Preclinical Data and Efficacy - Nimacimab demonstrated effective weight loss in a diet-induced obesity model after 25 days of treatment, showing a 23.5% weight loss when used alone, comparable to monlunabant and tirzepatide [5] - When combined with tirzepatide, nimacimab achieved greater than 30% weight loss, indicating an additive effect [5] - The study highlighted that nimacimab's weight loss was associated with beneficial changes in key hormones, glycemic control, and inflammatory markers [1][5] Group 2: Mechanism of Action - Nimacimab employs a non-competitive allosteric binding mechanism to the CB1 receptor, which may provide advantages over small molecules like monlunabant that compete for the receptor's active site [3][7] - In vitro data showed that nimacimab's potency remained stable even at higher concentrations of CB1 agonists, while monlunabant's potency significantly decreased under similar conditions [6][9] - The differentiated mechanism of nimacimab aims to achieve weight loss benefits without the neuropsychiatric side effects associated with current small molecule CB1 inhibitors [7][10] Group 3: Future Developments - Skye anticipates initial data from its Phase 2a study in obesity to be available in late Q3 or early Q4 2025, which will further assess nimacimab's efficacy [2][5] - The company is conducting a Phase 2 clinical trial to evaluate nimacimab's effects both as a monotherapy and in combination with GLP-1 receptor agonists [10]

Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [2] - The company aims to create first-in-class therapeutics by leveraging biologic targets with substantial human proof of mechanism [2] Clinical Development - Skye is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, specifically targeting obesity [2] - The trial is also assessing the combination of nimacimab with a GLP-1R agonist, Wegovy® [2] Upcoming Events - The executive team of Skye will be available for one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA [1]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2024 were $7.8 million, up from $1.6 million in Q4 2023, primarily due to clinical and manufacturing costs associated with the Phase IIa CBeyond study for nimacimab [30] - For the year ended December 31, 2024, R&D expenses totaled $18.7 million compared to $5.8 million in 2023, driven by clinical costs and increased discovery research efforts [31] - General and administrative expenses for Q4 2024 were $4.6 million, up from $2.5 million in Q4 2023, mainly due to stock-based compensation and professional services [32] - The net loss for the year ended December 31, 2024, was $26.6 million, a decrease from $37.6 million in 2023, attributed to the acquisition of nimacimab in-process R&D assets in 2023 [33] Business Line Data and Key Metrics Changes - The company has shifted focus from the development of SBI-100 to nimacimab, reallocating resources to achieve clinical milestones [11] - The CBeyond clinical trial for nimacimab saw rapid enrollment, completing 136 patients, exceeding the initial target of 120 [9] Market Data and Key Metrics Changes - The company views nimacimab as a differentiated alternative in the obesity treatment market, especially as the GLP-1 receptor agonist space becomes crowded [24] - Recent industry deals highlight the growing interest in non-incretin mechanisms for obesity treatment, which aligns with the company's strategy [24][81] Company Strategy and Development Direction - The company plans to engage with regulators for a Phase IIb dose-escalation study anticipated to start in Q2 2026, while strengthening manufacturing capabilities [22] - The strategic decision to extend the CBeyond trial to 52 weeks aims to gather more comprehensive safety and efficacy data, enhancing regulatory discussions [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in nimacimab's safety profile, noting no neuropsychiatric side effects in the Phase I study [16] - The company anticipates that the extended trial will yield additional data to support its regulatory package and therapeutic profile [19][20] Other Important Information - The company reported cash and cash equivalents of $68.4 million as of December 31, 2024, with an operating cash burn averaging $6.3 million per quarter [34][35] - The company has eliminated related party balances and remediated litigation matters during 2024 [34] Q&A Session Summary Question: What can be translated from preclinical model work regarding weight loss curves at 26 and 52 weeks? - Management acknowledged the strategic value of the extension for additional efficacy and safety data, but noted it is challenging to extrapolate preclinical data directly to human studies [40][42] Question: Will the DSMB reviews pick up any neuropsychiatric adverse events? - The independent Data Safety Monitoring Board (DSMB) reviews all safety data and has indicated no concerns, allowing the trial to continue as planned [50][51] Question: How does the enrollment completion affect the analysis and Phase IIb plans? - The completion of enrollment with 136 patients enhances the robustness of efficacy and safety analysis, but does not change the regulatory pathway [62][64] Question: What are the expectations for preclinical data to be presented in Q2? - The company plans to share a robust data set that includes biomarker work and differentiation around nimacimab's mechanism of action [68][71] Question: How does the company view the recent obesity deals in relation to nimacimab? - Management noted that the recent deals highlight the industry's shift towards non-incretin mechanisms, which aligns with nimacimab's unique positioning [81][86] Question: What is the plan for testing nimacimab in diabetic patients? - The company is excited about the potential to test nimacimab in diabetic populations, given its mechanism of action related to insulin sensitivity [132][134]

Financial Data and Key Metrics Changes - Research and development expenses for Q4 2024 were $7.8 million, up from $1.6 million in Q4 2023, primarily due to clinical and manufacturing costs associated with the Phase IIa CBeyond study for nimacimab [30] - For the year ended December 31, 2024, research and development expenses totaled $18.7 million, compared to $5.8 million in 2023, driven by increased clinical costs and employee-related benefits [31] - General and administrative expenses for Q4 2024 were $4.6 million, up from $2.5 million in Q4 2023, mainly due to stock-based compensation and professional services [32] - The net loss for the year ended December 31, 2024, was $26.6 million, a decrease from $37.6 million in 2023, attributed to the expensing of acquisition costs in 2023 [33] Business Line Data and Key Metrics Changes - The company has shifted focus from the development of SBI-100 to nimacimab, reallocating resources to achieve clinical milestones [11] - The CBeyond clinical trial for nimacimab saw over-enrollment, completing enrollment with 136 patients, exceeding the planned 120 patients [9] Market Data and Key Metrics Changes - The company views nimacimab as a differentiated alternative in the obesity treatment market, especially as the GLP-1 receptor agonist space becomes crowded [24] - Recent industry deals highlight the growing interest in non-incretin mechanisms for obesity treatment, validating the potential of CB1 inhibitors like nimacimab [81] Company Strategy and Development Direction - The company plans to engage with regulators for a Phase IIb dose-escalation study anticipated to start in Q2 2026, while also enhancing manufacturing capabilities [22] - The strategic decision to extend the CBeyond trial to 52 weeks aims to gather more comprehensive safety and efficacy data, which will support regulatory discussions [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in nimacimab's safety profile, noting no neuropsychiatric side effects in the Phase I study and ongoing positive reviews from the Data Safety Monitoring Board [16][50] - The company anticipates that the additional data from the extended trial will enhance understanding of nimacimab's capabilities and support its regulatory package [19] Other Important Information - The company reported cash and cash equivalents of $68.4 million as of December 31, 2024, with an operating cash burn averaging $6.3 million per quarter [34][36] - The company has eliminated related party balances and remediated litigation matters during 2024, improving its financial position [35] Q&A Session Summary Question: What can be expected from the 26 and 52-week readouts? - Management indicated that the extension study was strategic to gather longer-term efficacy and safety data, which is crucial for regulatory discussions [42][43] Question: How does the removal of the interim analysis affect the study's power? - The removal of the interim analysis preserves the study's power, allowing for a more robust efficacy and safety analysis with a larger patient dataset [60][100] Question: What feedback has been received from investigators regarding the study? - Investigators have shown strong enthusiasm for the obesity trials, contributing to the rapid enrollment pace [96] Question: Will there be additional DEXA scans during the extended study? - Yes, there will be a DEXA scan at the midpoint of the extension and another at the end of the treatment period to assess body composition changes [99] Question: How does the company view the potential for nimacimab in diabetic patients? - The company is excited about testing nimacimab in diabetic populations, as its mechanism may improve insulin sensitivity and address inflammation [132]

Financial Performance - Skye Bioscience reported a net loss of $9.7 million for Q4 2024, compared to a net loss of $4.4 million for the same period in 2023[20]. - The net loss for Q4 2024 was $9,746,479, compared to a net loss of $4,419,930 in Q4 2023, indicating an increase in losses of 120%[27]. - Basic loss per share for Q4 2024 was $(0.24), an improvement from $(0.36) in Q4 2023, reflecting a reduction in loss per share of 33%[27]. - Total operating expenses for the year ended December 31, 2024, were $30,192,718, down from $34,735,173 in 2023, representing a decrease of 13%[27]. Research and Development - Research and development (R&D) expenses for Q4 2024 were $7.8 million, a significant increase from $1.6 million in Q4 2023, primarily due to clinical trial costs for nimacimab[15]. - Skye's R&D expenses for the full year 2024 were $18.7 million, compared to $5.8 million in 2023, reflecting increased clinical trial activities[16]. - Research and development expenses for Q4 2024 were $7,793,156, a significant increase from $1,591,494 in Q4 2023, reflecting a growth of 388%[27]. - The Phase 2a trial's dosing has been extended to 52 weeks to enhance long-term safety and efficacy data[8]. - Enrollment in the Phase 2a CBeyond trial of nimacimab exceeded the target, completing at 136 patients, with top-line data expected in late Q3/early Q4 2025[6]. - The company is advancing toward monthly dosing of nimacimab to improve patient experience and adherence[10]. Financial Position - Cash and cash equivalents totaled $68.4 million as of December 31, 2024, expected to fund operations through at least Q1 2027[19]. - Cash and cash equivalents increased to $68,415,741 as of December 31, 2024, up from $1,256,453 in 2023, showing a growth of 5,444%[29]. - Total assets rose to $72,763,773 in 2024, compared to $11,940,411 in 2023, marking an increase of 509%[29]. - Stockholders' equity improved to $68,151,724 in 2024, compared to a deficit of $(2,131,818) in 2023, indicating a turnaround in equity position[29]. - The company reported a total current liabilities of $4,338,887 in 2024, down from $13,900,999 in 2023, a decrease of 69%[29]. Other Financial Metrics - General and administrative (G&A) expenses for Q4 2024 were $4.6 million, up from $2.5 million in Q4 2023, mainly due to non-cash stock-based compensation and professional services[17]. - Skye achieved a $4.2 million gain from the partial derecognition of contingent liabilities and a $2.0 million gain from insurance recoveries in 2024[21]. - The weighted average shares of common stock outstanding increased to 39,968,601 in Q4 2024 from 12,343,269 in Q4 2023, an increase of 224%[27]. - The company did not incur any costs to acquire IPR&D assets in 2024, compared to $21,215,214 in 2023, indicating a strategic shift in asset acquisition[27]. - The company plans to present preclinical data at scientific conferences in Q2 2025, alongside an analyst event during the American Diabetes Association sessions[19].

[Part I](index=4&type=section&id=PART%20I) [Business](index=5&type=section&id=Item%201.%20Business) The company is a clinical-stage biotech firm developing its lead candidate, nimacimab, for obesity treatment - Skye Bioscience is a clinical-stage biotechnology company focusing on **GPCR-modulating molecules** to treat obesity, with its lead candidate being **nimacimab**, a CB1 receptor targeting antibody[15](index=15&type=chunk) - The company is conducting the **"CBeyond" Phase 2a trial** for nimacimab, with top-line data anticipated in **late Q3 or early Q4 of 2025**[16](index=16&type=chunk) **Development Pipeline Status** | MOA | Disease | Discovery | Preclinical | Ph1 | Ph2 | Ph3 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Nimacimab** | | | | | | | | CB1 Receptor Inhibitor | Obesity | | | ✓ | **►** | | - The company's intellectual property portfolio includes **3 granted U.S. patents** and **38 foreign patents** for nimacimab, with expiration dates between **2035 and 2036**[57](index=57&type=chunk)[58](index=58&type=chunk) - As of March 19, 2025, the company has **16 full-time employees**, four of whom hold a Ph.D or MD degree[117](index=117&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) The company faces substantial risks from its reliance on a single clinical candidate and its history of financial losses - Principal risk factors include dependence on third parties, a history of losses, need for additional financing, and reliance on **nimacimab's clinical success**[128](index=128&type=chunk) **Historical Financial Losses** | Metric | FY 2024 | FY 2023 | | :--- | :--- | :--- | | **Net Loss** | $26,567,123 | $37,644,784 | | **Accumulated Deficit (as of Dec 31, 2024)** | $130,949,672 | | - The company is **heavily dependent on the success of nimacimab**, its only product candidate in clinical development[131](index=131&type=chunk) - The company will require **substantial additional financing** to complete the development of nimacimab beyond the current Phase 2a trial[135](index=135&type=chunk)[136](index=136&type=chunk) - As of December 31, 2024, executive officers, directors, and principal stockholders collectively owned approximately **71% of the company's outstanding common stock**[285](index=285&type=chunk) [Unresolved Staff Comments](index=67&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports that it has no unresolved staff comments - None[320](index=320&type=chunk) [Cybersecurity](index=67&type=section&id=Item%201C.%20Cybersecurity) The company maintains a cyber risk program based on the NIST framework, with oversight from the Audit Committee - The company's cyber risk management program is based on the **NIST Cybersecurity Framework** and includes annual third-party assessments[322](index=322&type=chunk) - The **Audit Committee** of the Board of Directors oversees the cybersecurity risk management program, receiving briefings at least annually[326](index=326&type=chunk) - While acknowledging the risk of future incidents, the company states that prior cybersecurity events have **not materially impacted** its business or financials[327](index=327&type=chunk) [Properties](index=68&type=section&id=Item%202.%20Properties) The company leases its principal executive and corporate offices in San Diego, California, until October 2026 - The company's principal executive offices are leased at 11250 El Camino Real Suite 100, San Diego, CA 92130, with the lease expiring on **October 31, 2026**[328](index=328&type=chunk) [Legal Proceedings](index=68&type=section&id=Item%203.%20Legal%20Proceedings) Material legal proceedings are detailed in Note 11 of the consolidated financial statements - For details on material legal proceedings, the report refers to **Note 11** of the financial statements[329](index=329&type=chunk) [Mine Safety Disclosures](index=68&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[330](index=330&type=chunk) [Part II](index=69&type=section&id=PART%20II) [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=69&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under "SKYE", and no cash dividends are anticipated - The company's common stock trades on the **Nasdaq Global Select Market** under the symbol **"SKYE"**[333](index=333&type=chunk) - As of March 19, 2025, there were **190 stockholders of record**[334](index=334&type=chunk) - The company has **never declared or paid a cash dividend** and does not expect to in the foreseeable future[335](index=335&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=69&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) The net loss decreased in 2024 while operating expenses rose, and liquidity improved significantly from equity financings - In 2024, the company raised combined net proceeds of **$83.6 million** from two private placement equity financings[342](index=342&type=chunk) - The company **eliminated its ocular program (SBI-100 OE)** after a Phase 2a trial did not meet its primary endpoint, redirecting resources to its metabolic program[345](index=345&type=chunk) - In Q4 2024, the company recovered **$9 million in restricted cash** after a favorable appeal in a material litigation matter and collected an additional **$2 million** from its insurance carrier[347](index=347&type=chunk) **Comparison of Operating Expenses (2024 vs 2023)** | Expense Category | 2024 ($) | 2023 ($) | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | 18,701,694 | 5,819,461 | 12,882,233 | 221% | | Cost to acquire IPR&D asset | 0 | 21,215,214 | (21,215,214) | (100)% | | General and administrative | 17,725,741 | 7,852,340 | 9,873,401 | 126% | **Net Loss and Loss Per Share (2024 vs 2023)** | Metric | 2024 | 2023 | | :--- | :--- | :--- | | **Net Loss** | $(26,567,123) | $(37,644,784) | | **Loss Per Share (Basic & Diluted)** | $(0.73) | $(5.37) | **Summary of Cash Flows (2024 vs 2023)** | Cash Flow Activity | 2024 ($) | 2023 ($) | | :--- | :--- | :--- | | **Operating Activities** | (25,237,480) | (13,952,178) | | **Investing Activities** | (245,615) | 6,596,456 | | **Financing Activities** | 83,562,181 | 16,443,270 | [Financial Statements and Supplementary Data](index=78&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) The financial statements show a reduced net loss and a shift from a stockholders' deficit to significant equity in 2024 **Consolidated Balance Sheet Highlights (as of Dec 31)** | Account | 2024 ($) | 2023 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | 68,415,741 | 1,256,453 | | Total Assets | 72,763,773 | 11,940,411 | | Total Liabilities | 4,612,049 | 14,072,229 | | Total Stockholders' Equity (Deficit) | 68,151,724 | (2,131,818) | **Consolidated Statement of Operations Highlights (Year Ended Dec 31)** | Account | 2024 ($) | 2023 ($) | | :--- | :--- | :--- | | Research and development | 18,701,694 | 5,819,461 | | General and administrative | 17,725,741 | 7,852,340 | | Net loss | (26,567,123) | (37,644,784) | | Loss per common share (Basic & Diluted) | (0.73) | (5.37) | - The company acquired nimacimab through the BRB Acquisition on August 18, 2023, for total consideration valued at **$21.6 million**, recorded as an IPR&D expense[487](index=487&type=chunk)[489](index=489&type=chunk)[490](index=490&type=chunk) - In the Cunning Lawsuit, the company won an appeal, leading to the recovery of a **$9 million cash bond** and a **$4.2 million gain** from a change in legal contingency[570](index=570&type=chunk)[571](index=571&type=chunk) - The company settled a lawsuit with its D&O insurance carrier, Partner Re, for **$2 million**, recognized as income from insurance recovery in 2024[573](index=573&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=78&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) This item is not applicable to the company - Not applicable[392](index=392&type=chunk) [Controls and Procedures](index=78&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective - Management concluded that the company's **disclosure controls and procedures were effective** as of the end of the period covered by the report[393](index=393&type=chunk) - Based on an assessment using the **COSO 2013 framework**, management concluded that the company's internal control over financial reporting was effective as of December 31, 2024[396](index=396&type=chunk)[397](index=397&type=chunk) [Other Information](index=79&type=section&id=Item%209B.%20Other%20Information) The company announced its 2025 Annual Meeting date and disclosed a director-affiliated Rule 10b5-1 stock sale plan - The 2025 Annual Meeting of Stockholders is scheduled for **June 6, 2025**[400](index=400&type=chunk) - On December 17, 2024, entities affiliated with a director entered into a **Rule 10b5-1 plan** to sell up to **2,000,000 shares** of common stock[404](index=404&type=chunk) [Part III](index=80&type=section&id=PART%20III) [Directors, Executive Officers and Corporate Governance](index=80&type=section&id=Item%2010.%20Directors,%20Executive%20Officers%20and%20Corporate%20Governance) Information on directors, officers, and governance is incorporated by reference from the 2025 Proxy Statement - Information required by this item is **incorporated by reference** from the company's definitive Proxy Statement for the 2025 Annual Meeting[408](index=408&type=chunk) [Executive Compensation](index=80&type=section&id=Item%2011.%20Executive%20Compensation) Details regarding executive compensation are incorporated by reference from the company's 2025 Proxy Statement - Information required by this item is **incorporated by reference** from the company's definitive Proxy Statement for the 2025 Annual Meeting[409](index=409&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=80&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Security ownership information is incorporated by reference from the company's upcoming 2025 Proxy Statement - Information required by this item is **incorporated by reference** from the company's definitive Proxy Statement for the 2025 Annual Meeting[410](index=410&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=80&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions,%20and%20Director%20Independence) Information on related party transactions and director independence is incorporated by reference from the 2025 Proxy Statement - Information required by this item is **incorporated by reference** from the company's definitive Proxy Statement for the 2025 Annual Meeting[412](index=412&type=chunk) [Principal Accountant Fees and Services](index=80&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Details on principal accountant fees and services are incorporated by reference from the 2025 Proxy Statement - Information required by this item is **incorporated by reference** from the company's definitive Proxy Statement for the 2025 Annual Meeting[413](index=413&type=chunk) [Part IV](index=81&type=section&id=PART%20IV) [Exhibits, Financial Statement Schedules](index=81&type=section&id=Item%2015.%20Exhibits,%20Financial%20Statement%20Schedules) This section lists the consolidated financial statements, the independent auditor's report, and all filed exhibits - This section includes the consolidated financial statements of Skye Bioscience, Inc, and the report from its independent registered public accounting firm, **Marcum LLP**[416](index=416&type=chunk) - A comprehensive list of exhibits filed with the Form 10-K is provided, including merger agreements, bylaws, and financing agreements[579](index=579&type=chunk)[580](index=580&type=chunk) [Form 10-K Summary](index=115&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company indicates that no Form 10-K summary is provided - None[583](index=583&type=chunk)

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company"), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024, along with key accomplishments and upcoming milestones. "Skye's prime accomplishment in 2024 was the initiation and rapid advanceme ...

Core Viewpoint - Skye Bioscience, Inc. is set to discuss its 2024 fourth quarter and full-year financial results in a conference call on March 20, 2025, indicating a focus on transparency and investor engagement [1][2]. Company Overview - Skye Bioscience is a clinical-stage biotechnology company dedicated to developing new therapeutic pathways for obesity and metabolic health disorders through next-generation molecules that modulate G-protein coupled receptors [3]. - The company is conducting a Phase 2 clinical trial for nimacimab, an antibody that inhibits CB1, and is also exploring its combination with a GLP-1R agonist (Wegovy®) [3]. Financial Communication - An earnings press release will be issued after market close on March 20, 2025, and a live webcast of the conference call will be available on the Skye Investor Relations website [1][2].

Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][3] - The company is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, and is also assessing its combination with a GLP-1R agonist (Wegovy®) [3] Industry Insights - The South by Southwest (SXSW) conference serves as a global platform for thought leaders and industry experts to discuss emerging trends in health and medtech, particularly in the context of weight loss medicine [2] - The panel session titled "Weighing in on Weight Loss Medicine" will explore the future of obesity management beyond GLP-1 drugs, indicating a shift towards innovative solutions in the obesity treatment landscape [2][1]

Company Overview - Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapeutic pathways for obesity and metabolic health disorders [1][3] - The company is leveraging biologic targets with substantial human proof of mechanism to create first-in-class therapeutics with clinical and commercial differentiation [3] Clinical Development - Skye is conducting a Phase 2 clinical trial for nimacimab, a negative allosteric modulating antibody that inhibits CB1, specifically targeting obesity [3] - The trial is also assessing the combination of nimacimab with a GLP-1R agonist (Wegovy®) [3] Upcoming Events - Punit Dhillon, the CEO of Skye, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on March 5, 2025, from 11:10 AM to 11:40 AM ET in Boston, MA [1][5] - A live and archived webcast of the presentation will be available on Skye's website [2]